Nicolai Wagtmann, EVP and CSO of Innate Pharma will take part in this event:
- Presentation on November 17th 2016 during the session Pioneering Novel checkpoint Pathways Beyond PD-1, PD-L1 and CTLA-4 at 9 AM : "Broadening The Scope: Targeting Checkpoint Receptors On Natural Kill Cells To Mount Anti- Tumour Immune Responses"
- Pannel discussion on November 17th 2016 at 3 PM : "Future Perspectives On The Development Of Immune Checkpoint Inhibitors"
Date